Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

– Preliminary Data from ATH434-202 Study Expected in 1H 2024 –
– ATH434-201 Study to Complete in November 2024 –

MELBOURNE, Australia and SAN FRANCISCO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders.

Dear Shareholders:

As we begin a new year, I wanted to take a moment to thank you for your support of Alterity, reflect on our accomplishments in 2023, and lay out our key milestones for 2024. We remain steadfastly committed to developing new treatments for individuals living with neurodegenerative diseases.

2023 was a critical year for us and I am pleased to report that we hit all of our intended milestones.

We have an extremely robust program evaluating neurodegenerative diseases with a current focus on Multiple System Atrophy, or MSA, a disease related to Parkinson’s. As a reminder, MSA is a rare and aggressive Parkinsonian disorder that rapidly progresses and causes profound disability. Although similar to Parkinson’s disease, affected individuals cannot adequately maintain their blood pressure or control bowel and bladder function – areas that drastically impair quality of life. The pathological hallmark of MSA is accumulation of the protein alpha-synuclein and neuron loss in multiple brain regions within the central nervous system. While some of the symptoms of MSA can be treated with available medications, currently there are no drugs that can slow disease progression and there is no cure.

We are looking to change the paradigm of treating MSA with our lead clinical development candidate ATH434, an orally administered agent discovered in house to target neurodegeneration. ATH434 acts by redistributing excess iron in the brain, reducing the protein α-synuclein, and rescuing neuronal function. Based on accumulated pre-clinical data and an understanding of how MSA develops and progresses, we believe ATH434 has excellent potential to treat MSA as well as Parkinson’s disease. Importantly, ATH434 has been granted Orphan Drug Designation (ODD) for the treatment of MSA by the U.S. FDA and the European Commission. ODD comes with many benefits including 7-10 years of market exclusivity, tax credits and fee reductions, as well as protocol assistance from each agency.